All articles tagged with #hiv treatment
A lawsuit filed by the ACLU of Idaho challenges a new state law that restricts public benefits for undocumented immigrants, including access to HIV/AIDS medication, citing vagueness and conflict with federal law, and raising concerns about public health and patient care. The law, set to take effect on July 1, limits benefits requiring verification of lawful U.S. residency, impacting vulnerable populations and healthcare providers.
In 2023, drugmakers increased prices on five widely used drugs without new clinical evidence, costing U.S. patients and insurers an additional $815 million, according to a report by the Institute for Clinical and Economic Review. The largest spending increase was for Biktarvy, an HIV treatment by Gilead Sciences, which saw a 5.9% wholesale price hike, resulting in $359 million more in spending. Gilead claims some study data were overlooked or rejected, challenging the report's findings.
Gilead Sciences reported a 7% increase in product sales excluding Veklury for the full year 2023, with Biktarvy sales up 14% and oncology sales up 37%. However, total fourth quarter 2023 revenue decreased by 4% to $7.1 billion compared to the same period in 2022, primarily due to lower Veklury and HIV sales, partially offset by higher oncology sales. The company also provided guidance for full-year 2024, expecting total product sales between $27.1 billion and $27.5 billion and diluted EPS between $5.15 and $5.55.
Researchers at Tokyo Medical and Dental University have made a significant breakthrough in the treatment of HIV-1, the virus responsible for AIDS. They have identified a compound called YSE028 that can activate latent HIV-1 in cells, potentially leading to more effective HIV treatments and even a cure. The compound activates a protein called protein kinase C (PKC) without causing significant toxicity to cells. Further research and clinical trials are needed to fully understand the implications and effectiveness of this compound in future HIV treatments.